Pharmacological and non-pharmacological strategiesin the integrated treatment of pain in neurorehabilitation Evidence and recommendations from theItalian Consensus Conference on Pain in Neurorehabilitation: Tamburini S et al.
Abstract: The interplay between pain and neurorehabilitation is very complex, in that pain may be a target for treatment, but can also have negative effects on neurorehabilitation procedures. Moreover, side effects of drugs, which are currently used to treat pain, may negatively infuence rehabilitation outcomes. …
Consensus Guidelines for Botulinum Toxin Therapy: General Algorithms and Dosing Tables for Dystonia and Spasticy: Dressler D et al.
Abstract: Botulinum toxin (BT) therapy is a complex and highly individualised therapy defined by treatment algorithms and injection schemes describing its target muscles and their dosing. …
The updated European Consensus 2009 on the use of Botulinum toxin for children with cerebral palsy: Heinen F et al.
Abstract: An interdisciplinary European group of clinical experts in the field of movement disorders and experienced Botulinum toxin users has updated the consensus for the use of Botulinum toxin in the treatment of children with cerebral palsy (CP). …
Intrathecal Baclofen Therapy in Germany: Proceeding of IAB – Interdisciplinary Working Group for Movement Disorders Consensus Meeting: Dressler D et al.
Abstract: Continuous intrathecal Baclofen application (ITB) through an intracorporeal pump system is widely used in adults and children with spasticity of spinal and supraspinal origin. Currently, about 1200 new ITB pump systems are implanted in Germany each year. ….
Strategies for Treatment of Dystonia: Special Task Force on Treatment of Dystonia formed by IAB – Interdisciplinary Working Group for Movement Disorders: Dressler D et al.
Abstract: Treatment of dystonias is generally symptomatic. To produce sufficient therapy effects, therefore, frequently a multimodal and interdisciplinary therapeutic approach becomes necessary, combining botulinum toxin therapy, deep brain stimulation, oral antidystonic drugs, adjuvant drugs and rehabilitation therapy including physiotherapy, occupational therapy, re-training, speech therapy, psychotherapy and sociotherapy ….
Botulinum Toxin Therapy for Treatment of Spasticity in Multiple Sclerosis: Review and Recommendations of the IAB-Interdisciplinary Working Group for Movement Disorders Task Force: Dressler D et al.
Abstract Botulinum toxin (BT) therapy is an established treatment of spasticity due to stroke. For multiple sclerosis (MS) spasticity this is not the case. IAB-Interdisciplinary Working Group for Movement Disorders formed a task force to explore the use of BT therapy for treatment of MS spasticity. ….
Defining Spasticity: A New Approach Considering Current Movement Disorders Terminology and Botulinumtoxin Therapy Review and Recommendations of IAB – Interdisciplinary Working Group for Movement Disorders Task Force: Dressler D et al.
Abstract: Spasticity is a symptom occurring in many neurological conditions including stroke, multiple sclerosis, hypoxic brain damage, traumatic brain injury, tumours and heredodegenerative diseases. ….
Review article – The updated European Consensus 2009 on the use of Botulinum toxin for children with cerebral palsy: Heinen F et al.
a b s t r a c t An interdisciplinary European group of clinical experts in the field of movement disordersand experienced Botulinum toxin users has updated the consensus for the use of Botulinum toxin in the treatment of children with cerebral palsy (CP). ….